Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
Yoshihito Nagura(Kasugai Municipal Hospital), Yasuhito Tanaka(Kumamoto University), Masataka Tsuge(Hiroshima University), Hiromi Kataoka(Mizuho (Japan)), Koji Fujita(Kagawa University), Etsuko Iio(Nagoya City University), Akihiro Matsumoto(Shinshu University), Masanori Atsukawa(Nippon Medical School), Takako Inoue(Kaneka (United States)), Tsunamasa Watanabe(St. Marianna University School of Medicine), Masaru Enomoto(Osaka City University), Hiroki Ikeda(St. Marianna University School of Medicine), Takeshi Matsui(Nagoya City University), Jong‐Hon Kang(Teine Keijinkai Hospital), Kentaro Matsuura(Nagoya City University), Eiji Tanaka(Shinshu University), Masakuni Tateyama(Kumamoto University), Shuhei Nishiguchi(Osaka City General Hospital), Chiaki Okuse(St. Marianna University School of Medicine)
Cited by 9
Related Papers
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
|Hepatology|1990|1.2k
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan
|Hepatology|2001|418
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
|Proceedings of the National Academy of Sciences|2019|241